سعر سيناجيس 100 مجم /مل حقن 2026

Palivizumab 100 mg/ml solution for intramuscular injection; 1 vial (listed as net price).

• Prevention of serious lower respiratory tract disease requiring hospitalisation caused by RSV in high-risk children: born at <=35 weeks and <6 months old at season onset; <2 years with bronchopulmonary dysplasia treated within 6 months; <2 years with haemodynamically significant congenital heart diseasePopulation: High-risk infants/childrenEuropean Medicines Agency

• Common: fever, rash, injection site reaction. Most serious: anaphylaxis and acute hypersensitivity reactions.International label, same product · European Medicines Agency

• Hypersensitivity to palivizumab, any excipient or other humanised monoclonal antibodies.International label, same product · European Medicines Agency

• Anaphylaxis and anaphylactic shock (some fatal) reported; treatment for severe hypersensitivity must be immediately available.International label, same product · European Medicines Agency
• Moderate-severe acute infection or febrile illness may warrant delay; use with caution in thrombocytopenia or coagulation disorders; record brand and batch number.International label, same product · European Medicines Agency

• Not relevant: Synagis is not indicated for use in adults; no fertility, pregnancy or lactation data.International label, same product · European Medicines Agency

• Palivizumab: Binds the A antigenic site of the RSV fusion protein, neutralising RSV subtypes A and B and inhibiting fusion.